NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Hyperion DeFi, Inc. (HYPD) Stock Analysis

Hyperion DeFi, Inc. (HYPD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HYPD

$3.10

+$0.13 (+4.20%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HYPD with… →

HYPD Key Statistics

As of Oct 21, 2026
Trading
Open
$3.07
Previous Close
$2.98
Day's Range
3.04–3.18
52-Week Range
2.34–9.13
Volume
144.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.52
Valuation
Market Cap
$47.13M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.65
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.46
Financials (FY)
Revenue (FY)
$813.46K+1,318.75%
Net Income (FY)
−$45.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
474.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
15.20M
1-Year Return
−58.89%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
464.46K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HYPD closed at $3.10, −58.89% over 1 year.

Hyperion DeFi, Inc. (HYPD) has a market capitalization of $47.13M.

In fiscal 2025, HYPD reported revenue of $813.46K.

HYPD Stock Return by Calendar Year

Hyperion DeFi, Inc. (HYPD) return since Jan 2018: what $10,000 became

1 year
$10,000 $4,111
−58.89%
5 years
$10,000 $65
−99.35%
Since Jan 2018
$10,000 $39
−99.61%

If you had invested $10,000 in Hyperion DeFi, Inc. (HYPD) at the close on January 25, 2018, the earliest close on record here, it would have been worth $39 at the close on October 21, 2026: −99.61% in total, −46.99% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.92%
2025−69.52%
2024−92.98%
2023+27.61%
2022−59.25%
2021−33.99%
2020+35.27%
2019+57.19%
2018−71.27%

As of October 21, 2026.

HYPD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$813.46K−$45.31M−5,570.6%
2024$57.34K−$49.82M−86,888.6%
2023$3.79K−$27.26M−719,859.9%
2022$0.00−$28.01M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$813.46K$510.17K−$18.98M−$45.31M−5,570.6%
2024$57.34K−$3.87M−$37.53M−$49.82M−86,888.6%
2023$3.79K−$12.22K−$25.41M−$27.26M−719,859.9%
2022$0.00$0.00−$26.91M−$28.01M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HYPD Valuation vs Biotechnology Median

Median of 608 stocks
MetricHYPDBiotechnology medianvs median
P/S ratio33.6513.30153% above
Profit margin474.87%−38.31%513.2 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Hyperion DeFi, Inc. (HYPD) at $47.13M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 9.

HYPD last closed at $3.10 on October 21, 2026. That is +$0.13 (+4.20%) against the previous close. The 52-week range on file runs from $2.34 to $9.13. The latest close sits 32.48% above that 52-week low.

Financial Health

In fiscal 2025, Hyperion DeFi, Inc. reported revenue of $813.46K. That is +1,318.75% against the prior fiscal year, when revenue was $57.34K. The same year closed with a net loss of $45.31M. Profit margin runs at 474.87%. That is 513.2 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −6.46.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $813.46K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 33.65 times revenue. On price-to-sales that is 153% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 2.52. Annualized volatility over the trailing 8 years is 126.87%. The trailing one-year total return is −58.89%. Across 5 years the annualized return works out at −63.49%.

Growth & Income

The record shows no dividend for HYPD.

Across the complete calendar years on file, 2019 returned +57.19% and 2024 returned −92.98%. Of the 8 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −12.92% year to date.

Peer Comparison

Hyperion DeFi, Inc. (HYPD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Hyperion DeFi, Inc. HYPD $47.13M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Hyperion DeFi, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Hyperion DeFi, Inc.

Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem. It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.

Visit website →